Clinical Trial Update: A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML [NA]

View source ↗

Summary

A single-arm prospective trial evaluating a conditioning regimen of total body irradiation (TBI) plus Busulfan-Melphalan (BUMEL) before salvage hematopoietic st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• BUSULFAN (Busulfan)
• Melphalan (Melphalan)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Relapsed or Refractory Acute Myeloid Leukemia | NA | Status: RECRUITING